The 4 Phases of Clinical Trials Explained With Real-World Examples

A compound that eliminates cancer cells in a laboratory dish looks, for a brief moment, like a miracle. It is not one yet. Out of every ten drug candidates that enter human testing, roughly nine will fail somewhere along the way, and the one that succeeds will typically take a decade or more and over a billion dollars to reach a pharmacy shelf. That brutal attrition rate is not a sign of a broken system. It is the system working exactly as designed.

Between an early laboratory discovery and an approved medication lies a long, deliberately staged gauntlet built to answer one question at a time rather than all at once: is it safe, does it work, does it work better than what already exists, and does it hold up once millions of real people start taking it. That gauntlet is the four-phase clinical trial system, and understanding exactly what each phase proves, and how often treatments actually survive it, explains both why drug development takes so long and why an approved medication deserves the trust it carries.

Clinical Trial Success Rates at a Glance

Before walking through each phase individually, the numbers tell their own story about just how selective this process really is. Industry-wide data compiled by the Biotechnology Innovation Organization, tracking nearly 10,000 phase transitions across a decade of drug development, offers some of the most cited benchmarks in the field.

Success rates also vary dramatically by disease area. Vaccines for infectious diseases have historically shown some of the highest overall approval odds, with roughly one in three candidates eventually succeeding, while oncology drugs face the steepest climb, with some analyses placing cancer drug approval odds as low as 3 to 5 percent from first-in-human testing to market. Rare disease treatments, aided by smaller, more targeted trials and expedited regulatory pathways, tend to succeed considerably more often than treatments for common chronic diseases affecting large, diverse patient populations.

First, What Is a Clinical Trial?

A clinical trial is a research study conducted in human participants, designed to answer specific questions about a treatment’s safety, effectiveness, or optimal use. This differs from preclinical research, which takes place in laboratory settings and animal models before any human ever receives the treatment.

Different phases of clinical trials exist because different questions require different study designs. Early questions focus narrowly on safety and appropriate dosing, while later questions address whether a treatment actually works better than existing options across a broad, diverse population.

Phase 1: Is the Treatment Safe Enough to Study Further?

Phase 1 trials primarily evaluate safety and tolerability rather than effectiveness. These trials typically involve a small group, often 20 to 100 participants, sometimes healthy volunteers and sometimes patients with the target condition, depending on the treatment being studied.

Researchers commonly use a dose escalation design, starting with a very low dose and gradually increasing it while closely monitoring for adverse effects. For certain treatments, researchers also study pharmacokinetics, how the body processes the drug, and pharmacodynamics, how the drug affects the body. It is important to understand that passing Phase 1 does not mean a treatment has been proven effective. It means the treatment has shown an acceptable safety profile at the doses studied.

Roughly two-thirds of drug candidates that enter Phase 1 successfully advance to Phase 2, a comparatively high pass-through rate that reflects the phase’s narrow, achievable goal. The failures that do happen here tend to be serious ones, most often unexpected toxicity or intolerable side effects discovered even at low doses, findings that can end a compound’s development immediately regardless of how promising it looked in the lab. Phase 1 trials typically take about one to two years to complete, and because they usually involve small, closely monitored groups, they represent the smallest financial investment of any trial phase, even though the science involved is far from simple.

Phase 2: Does It Show Evidence of Benefit?

Phase 2 trials shift focus toward preliminary evidence of effectiveness while continuing to monitor safety in a somewhat larger group, typically ranging from a few dozen to several hundred participants who have the condition the treatment targets.

These trials often explore different doses and treatment regimens to identify which approach shows the most promising balance of benefit and safety. Study design varies considerably depending on the disease being studied, with some Phase 2 trials including a comparison group and others using a single-arm design, particularly for rare conditions with few available participants.

Phase 2 is where drug development goes to die. Only about 3 in 10 candidates that enter this phase make it through to Phase 3, making it by a wide margin the least forgiving stage in the entire process. The reasons are fairly consistent across therapeutic areas: a treatment that was perfectly safe in a small Phase 1 group simply fails to produce a meaningful clinical benefit once tested against the actual disease, or side effects that were tolerable in a handful of participants become a genuine problem once dosing continues over a longer period in more patients. Because of this steep drop-off, many drug developers now describe Phase 2 as the single riskiest, and most closely watched, checkpoint in the entire approval pathway.

Phase 3: Does It Work Compared With Existing Options?

Phase 3 trials represent the most rigorous test before a potential regulatory submission. These trials typically enroll hundreds to thousands of participants across multiple research sites, often including diverse populations to better represent how the treatment might perform in real-world use.

A comparison group, frequently receiving an existing standard treatment or a placebo where ethically appropriate, allows researchers to determine whether the new treatment offers a meaningful benefit. Phase 3 trials also generate the safety data needed to identify less common side effects that a smaller Phase 1 or Phase 2 trial might not have detected. Successful Phase 3 results form the primary evidence base that regulatory agencies such as the FDA review when deciding whether to approve a treatment.

Roughly 58 percent of drugs that begin Phase 3 testing go on to formal regulatory filing, meaning more than 4 in 10 candidates still fail even at this late, expensive stage. That failure rate carries an outsized financial sting, since Phase 3 trials consume an estimated 35 percent of all pharmaceutical research and development spending and around 60 percent of total clinical trial costs industry-wide, simply because of the sheer scale needed to enroll thousands of participants across dozens or hundreds of sites. A Phase 3 failure after years of investment and patient participation is widely regarded as one of the most painful setbacks in the entire drug development pipeline, which is why sponsors typically will not advance a candidate to this stage without strong supporting evidence from Phase 2.

Phase 4: What Happens After Approval?

Phase 4 trials, also called post-marketing studies, occur after a treatment reaches the general public. These studies monitor long-term safety across a much larger and more diverse population than any clinical trial could feasibly enroll, capturing rare adverse effects that only become statistically visible once thousands or millions of people have used the treatment.

Phase 4 research also examines real-world effectiveness, since patients in everyday clinical practice often differ from the more controlled populations enrolled in earlier trial phases. Additional research questions, such as effectiveness in specific subgroups or optimal long-term dosing, frequently emerge from this phase.

Once a drug clears regulatory filing, its odds improve dramatically: roughly 85 percent of applications submitted for final approval succeed, a figure that reflects how thoroughly a candidate has already been vetted by the time it reaches this stage. That said, approval is not the finish line it might appear to be. Post-marketing surveillance has led to significant label changes, new safety warnings, and, in a small number of well-documented cases, complete market withdrawal after rare but serious risks became apparent only once a drug reached widespread use. This is precisely why Phase 4 monitoring, though it receives far less public attention than the earlier phases, remains a permanent and essential part of a drug’s lifecycle rather than a formality.

One Treatment’s Journey Through the Four Phases

Consider a hypothetical compound identified in laboratory research as a promising treatment for a chronic inflammatory condition. This example is illustrative only and does not describe an actual product, but its numbers reflect realistic industry-wide odds at each stage.

The compound first moves through Phase 1, where 60 healthy volunteers receive gradually increasing doses over several weeks, confirming an acceptable safety profile with only mild, temporary side effects; statistically, it now sits among the roughly two-thirds of candidates that clear this bar.

It then advances to Phase 2, enrolling 200 patients with the target condition, where researchers identify a specific dose that shows meaningful symptom improvement compared to a placebo group; getting this far already places it among a minority of Phase 2 entrants, since most candidates fail at exactly this stage.

Phase 3 follows, enrolling 3,000 patients across dozens of research sites worldwide, comparing the new treatment directly against the current standard therapy over a full year; success here means beating odds that see more than 4 in 10 Phase 3 candidates fall short. Assuming favorable results, the sponsor submits this data to regulatory authorities for review, entering the roughly 85 percent of filings that ultimately succeed.

Following approval, Phase 4 monitoring continues for years, tracking outcomes across hundreds of thousands of patients in real-world clinical use. Multiplied across all four stages, this compound’s overall odds of ever reaching a patient’s medicine cabinet, from its very first human dose, were only around 1 in 10.

Trends Reshaping How Clinical Trials Are Run

Clinical trial design has changed considerably even in the past decade, and several trends are actively working to improve on the odds described above. Adaptive trial designs now allow researchers to adjust dosing, sample size, or even which treatment arm continues partway through a study, based on early results, rather than waiting until a trial’s rigid conclusion to learn whether an approach is working.

Real-world evidence, drawn from electronic health records and registries outside of formal trials, is increasingly used to supplement traditional trial data, particularly for rare diseases where recruiting a large enough Phase 3 population is genuinely difficult.

Biomarker-driven patient selection has also reshaped how trials are designed, allowing researchers to enroll only the patients most biologically likely to respond to a treatment rather than a broader, less targeted population, a shift that has measurably improved success rates in fields like oncology where genetic profiling can identify the right patients upfront.

Decentralized trials, which rely on telehealth visits, at-home testing kits, and remote monitoring devices rather than requiring every participant to travel to a physical research site, expanded significantly in recent years and continue to grow, since they meaningfully reduce the recruitment and retention challenges that have historically slowed Phase 3 trials in particular. Together, these shifts are aimed squarely at the industry’s most persistent problem: a process that still fails roughly nine times out of every ten attempts.

Clinical Trial Phase Does Not Tell the Whole Story

Knowing a trial’s phase alone does not reveal how rigorous or reliable its findings are. Several additional design elements matter just as much. Randomization, assigning participants to treatment groups by chance, reduces bias in group comparisons. Blinding, keeping participants or researchers unaware of group assignment, prevents expectations from influencing reported outcomes. Control groups provide a baseline for comparison, while primary endpoints define exactly what outcome the trial is designed to measure.

Sample size affects how confidently researchers can draw conclusions, and inclusion and exclusion criteria determine how broadly the results can be generalized to the wider population. Finally, statistical significance, indicating a result is unlikely to be due to chance, is not the same as clinical significance, which asks whether the effect is large enough to matter meaningfully for patients.

How Patients Can Evaluate a Clinical Trial

Anyone considering participation in a clinical trial benefits from asking several key questions. Eligibility criteria determine whether a person qualifies to participate at all. Understanding the specific risks and potential benefits, the trial location and time commitment, and the trial’s sponsor and current phase all inform a well-considered decision.

The trial’s primary outcome measure clarifies exactly what the study is trying to determine, and the informed consent process should thoroughly explain all of this before any participant agrees to join. Bringing specific questions directly to the research team is always appropriate and expected.

The Role of Regulatory Agencies Throughout the Process

Regulatory agencies, such as the FDA in the United States or the EMA in Europe, are involved well before a treatment reaches Phase 3. Early-phase trial designs typically require regulatory clearance before they can begin, and agencies often provide guidance to sponsors on trial design to ensure the resulting data will be sufficient for a future approval decision. This ongoing dialogue between researchers and regulators is intended to prevent a sponsor from investing years into a large trial that ultimately fails to answer the specific questions regulators need addressed.

Following a successful Phase 3 trial, sponsors submit a comprehensive application containing all accumulated trial data for formal regulatory review. This review process itself can take many months, involving detailed examination of both effectiveness data and the complete safety profile observed across all trial phases combined.

Why Some Treatments Never Reach Phase 3 or Approval

Most treatments that enter clinical trials never reach approval. Safety problems identified in earlier phases can halt development immediately. Insufficient effectiveness, where a treatment fails to outperform existing options or a placebo by a meaningful margin, accounts for a large share of failures, particularly at the Phase 2 and Phase 3 stages. Manufacturing challenges at scale, difficulty recruiting enough eligible participants, and statistical or design limitations that undermine confidence in the results can all end a treatment’s development regardless of its early promise.

Each phase of clinical trials exists to answer a distinct question, and passing one phase never guarantees success in the next. This staged structure, while slow, is precisely what allows patients and clinicians to eventually trust that an approved treatment has been genuinely tested for both safety and effectiveness.

This article provides general educational information about the clinical trial process and does not constitute medical advice. Anyone considering clinical trial participation should discuss the decision with a healthcare provider and the research team involved.

FAQ

Q: What are the four phases of clinical trials?

A: The four phases are Phase 1, focused on safety; Phase 2, focused on preliminary effectiveness; Phase 3, focused on confirming effectiveness against existing options; and Phase 4, focused on long-term monitoring after approval. Each phase builds on evidence gathered in the previous one.

Q: What happens in Phase 1?

A: Phase 1 trials involve a small group of participants and primarily test safety and tolerability, often using a dose escalation design. Passing Phase 1 does not confirm a treatment is effective, only that it has an acceptable safety profile at the doses tested.

Q: Is Phase 2 better than Phase 1?

A: Phase 2 is not “better,” but it addresses a different question, focusing on preliminary evidence of effectiveness in a larger group of patients with the target condition. Both phases are necessary steps rather than competing measures of quality.

Q: What is a Phase 3 clinical trial?

A: A Phase 3 trial is a large-scale study, often involving thousands of participants, designed to confirm effectiveness compared to existing treatments or a placebo. Results from Phase 3 trials form the primary basis for regulatory approval decisions.

Q: What is a Phase 4 clinical trial?

A: A Phase 4 trial, or post-marketing study, monitors a treatment’s long-term safety and real-world effectiveness after it has already been approved and is in general use. These studies can detect rare side effects not visible in earlier, smaller trials.

Q: What percentage of drugs make it through all four phases?

A: Industry data suggests only about 1 in 10 drug candidates that enter Phase 1 testing eventually win regulatory approval. Phase 2 has the steepest drop-off, with roughly 70 percent of candidates failing at that stage alone.

Q: How can someone find a clinical trial?

A: Registries such as ClinicalTrials.gov list actively recruiting studies searchable by condition, location, and trial phase. A healthcare provider can also help identify trials relevant to a specific diagnosis.

Q: Can clinical trials be stopped?

A: Yes, trials can be stopped early due to safety concerns, clear evidence of ineffectiveness, or, in some cases, early evidence of strong benefit that makes continuing a placebo group unethical. Independent safety monitoring boards oversee these decisions throughout a trial.